We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App





Disposable Biosensor Platform to Enable COVID-19 Testing at Point of Care

By LabMedica International staff writers
Posted on 13 May 2021
Print article
Image: Disposable Biosensor Platform to Enable COVID-19 Testing at Point of Care (Photo courtesy of GBS, Inc.)
Image: Disposable Biosensor Platform to Enable COVID-19 Testing at Point of Care (Photo courtesy of GBS, Inc.)
A small, printable organic strip has been designed to put the power of accurate, timely diagnosis of COVID-19 in the hands of patients and their primary health practitioners.

The Wyss Institute for Biologically Inspired Engineering at Harvard University (Boston, MA, USA) is integrating GBS, Inc.’s (New York, NY, USA) world-first Biosensor Platform technology with a specialized nanomaterial coating. This gel-like coating allows the detection of IgM and/or igG antibodies which indicates a person’s current or previous exposure to the SARS-CoV-2 virus, and thus, a potential infection with COVID-19. Further development could result in a chewing-gum sized diagnostic ‘strip’ to be used as a diagnostic tool for COVID-19 testing at point of care.

Through a study, GBS and the Wyss Institute intend to validate the performance and the feasibility of the collaboratively developed electrochemical assay built on the GBS biosensor strip and the Wyss Institute’s eRapid electro-chemical sensing platform for the detection of IgG antibodies. The research team at Harvard University’s Wyss Institute will receive anonymized, de-identified, infected and uninfected human serum and saliva samples of COVID-19 patients, with at least 35 post-pandemic positive samples and 35 negative samples which may include pre-pandemic negative samples from healthy donors.

“We are hopeful that this novel diagnostic sensor technology will be able to make a dent into the spread of SARS-CoV-2 by enabling the broad monitoring of immunity to the virus worldwide, including in individuals with active infection, and those who have overcome an infection or received one of the vaccines,” said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D. who developed eRapid with Wyss Senior Staff Scientist Pawan Jolly, Ph.D.

Related Links:
GBS, Inc.
Wyss Institute for Biologically Inspired Engineering at Harvard University


New
Gold Supplier
SARS-CoV-2 IgG ELISA Kit
NovaLisa SARS-CoV-2 IgG
New
Silver Supplier
Third Party Immunoassay QC
Multichem IA Plus
New
COVID-19 Antigen Rapid Test
COVID-19 Antigen RT (NP Swab)
New
Silver Supplier
COVID-19 IgM & IgG Quality Control
COVID-19 IgM & IgG Quality Control

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.